Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delafloxacin vs Moxifloxacin in CABP
NCT02679573Phase 3Completed
- Sponsor
- Melinta Therapeutics
- Start
- Dec 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of delafloxacin in community-acquired bacterial pneumonia (CAP), sponsored by Melinta Therapeutics. Started Dec 2016; status: completed.
02
Drugs
delafloxacin
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT02679573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02679573.